183490.KQ
Enzychem Lifesciences Corporation
KOE · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 990.00
−2.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 67.8B | 67.8B | 77.4B | 76.0B | 26.6B |
| Cost of Revenue | 64.6B | 65.3B | 73.1B | 71.7B | 25.0B |
| Gross Profit | 3.2B | 2.5B | 4.3B | 4.3B | 1.6B |
| Operating Expenses | |||||
| R&D Expense | 2.7B | 3.5B | 4.4B | 5.4B | 6.6B |
| SG&A Expense | 9.3B | 17.2B | 6.4B | 12.6B | 9.7B |
| General & Admin Expense | 5.7B | 2.1B | 1.9B | 2.1B | 1.8B |
| Selling & Marketing Expense | 3.6B | 3.6B | 4.4B | 4.1B | 2.8B |
| Other Expenses | 9.4B | — | 6.7B | — | 140.7M |
| Total Operating Expenses | 21.5B | 20.8B | 17.5B | 18.0B | 16.4B |
| Cost and Expenses | 86.0B | 86.0B | 90.6B | 90.4B | 41.4B |
| Operating Income (EBIT) | (18.3B) | (18.3B) | (13.2B) | (14.4B) | (14.8B) |
| Non-Operating | |||||
| Interest Income | 3.8B | 3.8B | 5.2B | 5.5B | 4.0B |
| Interest Expense | 201.5M | 201.5M | 238.7M | 620.1M | 10.0B |
| Net Interest Income | 3.6B | 3.6B | 5.0B | 4.9B | (6.1B) |
| Other Non-Op Income/Expense | 30.9M | 30.9M | (8.9B) | 4.5B | (10.8B) |
| Non-Operating Income (excl Interest) | (9.1B) | 5.0B | 8.7B | (5.1B) | 748.4M |
| EBT (Pre-Tax Income) | (18.2B) | (18.2B) | (22.1B) | (9.9B) | (25.6B) |
| Income Tax Expense | (142.6M) | (147.2M) | 3.1M | (476.3M) | (488.3M) |
| Bottom Line | |||||
| Net Income | (18.1B) | (18.1B) | (22.1B) | (9.3B) | (25.1B) |
| Earnings from Cont. Ops | (18.1B) | (18.1B) | (22.1B) | (9.4B) | (25.1B) |
| Earnings from Discont. Ops | — | — | — | (26.9M) | — |
| Bottom Line Net Income | (18.1B) | (18.1B) | (22.1B) | (9.3B) | (25.1B) |
| Per Share | |||||
| Basic EPS | (₩235) | (₩235) | (₩270) | (₩110) | (₩318) |
| Diluted EPS | (₩235) | (₩235) | (₩270) | (₩110) | (₩318) |
| Revenue Per Share | ₩796 | ₩796 | ₩944 | ₩895 | ₩338 |
| Shares | |||||
| Basic Shares Outstanding | 85.1M | 85.1M | 82.0M | 84.9M | 78.8M |
| Diluted Shares Outstanding | 85.1M | 85.1M | 82.0M | 84.9M | 78.8M |
| Profitability Metrics | |||||
| EBITDA | (15.1B) | (15.1B) | (18.4B) | (5.8B) | (13.2B) |
| D&A | 3.1B | 3.1B | 3.5B | 3.5B | 2.4B |
| EBIT | (13.3B) | (18.3B) | (21.8B) | (9.3B) | (15.6B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025